Drugs / ImMucin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01232712 | Sep 2010 → May 2013 | plasma cell myeloma | Vaxil Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00162500 | — | plasma cell myeloma | Hadassah Medical Organization | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ImMucin | “The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).” NCT00162500 ↗ |
| Modality | Peptide | “ImMucin, a novel peptide vaccine” NCT00162500 ↗ |
| Route | Subcutaneous | “Intradermal or subcutaneous injections” NCT01232712 ↗ |
| Target | MUC1 | “Peptide Vaccine (MUC-1)” NCT00162500 ↗ |